Zacks Investment Research upgraded shares of Lantheus Holdings Inc. (NASDAQ:LNTH) from a hold rating to a buy rating in a research note released on Wednesday. The brokerage currently has $9.00 target price on the stock.
According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “
Several other analysts have also commented on the stock. Jefferies Group increased their target price on shares of Lantheus Holdings from $8.00 to $12.00 and gave the company a buy rating in a research note on Monday, August 29th. Credit Suisse Group AG set a $4.00 target price on shares of Lantheus Holdings and gave the company a hold rating in a research note on Friday, August 5th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $7.80.
Shares of Lantheus Holdings (NASDAQ:LNTH) opened at 7.77 on Wednesday. Lantheus Holdings has a 12 month low of $1.76 and a 12 month high of $10.10. The company’s 50-day moving average is $8.46 and its 200-day moving average is $4.60. The stock has a market capitalization of $236.11 million, a PE ratio of 8.77 and a beta of 0.45.
Lantheus Holdings (NASDAQ:LNTH) last released its earnings results on Thursday, August 4th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.06 by $0.18. Lantheus Holdings had a net margin of 9.00% and a negative return on equity of 11.75%. The business earned $78 million during the quarter, compared to analyst estimates of $72.66 million. Equities research analysts expect that Lantheus Holdings will post $0.55 earnings per share for the current fiscal year.
Large investors have recently modified their holdings of the stock. BlackRock Institutional Trust Company N.A. increased its stake in shares of Lantheus Holdings by 28.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 194,308 shares of the company’s stock valued at $367,000 after buying an additional 42,971 shares during the period. Spark Investment Management LLC increased its stake in shares of Lantheus Holdings by 541.2% in the first quarter. Spark Investment Management LLC now owns 106,100 shares of the company’s stock valued at $200,000 after buying an additional 89,553 shares during the period. State Street Corp increased its stake in Lantheus Holdings by 10.3% in the first quarter. State Street Corp now owns 106,233 shares of the company’s stock worth $200,000 after buying an additional 9,909 shares during the last quarter. Gabelli Funds LLC increased its stake in Lantheus Holdings by 22.2% in the second quarter. Gabelli Funds LLC now owns 165,000 shares of the company’s stock worth $606,000 after buying an additional 30,000 shares during the last quarter. Finally, GSA Capital Partners LLP increased its stake in Lantheus Holdings by 3.7% in the second quarter. GSA Capital Partners LLP now owns 154,322 shares of the company’s stock worth $566,000 after buying an additional 5,500 shares during the last quarter. Institutional investors and hedge funds own 30.15% of the company’s stock.
Lantheus Holdings Company Profile
Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.